Merck KGaA : Q2 2018 results: group EBITDA pre missed expectations – but due to temporary factors
>Group EBITDA missed consensus due to temporary effects in Life Science; Performance Materials better than expected - Merck posted Q2 2018 results today (09 Aug) with group revenue of € 3,714m slightly exceeding our estimate and consensus* (€ 3,613m; Oddo BHFe: € 3,652.7m). However, group EBITDA pre at € 920m missed cs by 3.2% (cs: € 951m) and our estimate by 2% (€ 939m). *Consensus/cs = Vara consensus throughout this note.EBITDA miss mainly due to tempor...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.